与癌症治疗相关的唾液功能障碍
Cristina Paz1, Annemarie Glassey1, Abigail Frick1
1Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
The Journal of clinical investigation
|September 3, 2024
概括
化疗和放射治疗等癌症治疗可以导致口腔干燥,影响患者的生活质量. 这篇综述探讨了唾液腺功能,治疗副作用,以及 Xerostomia 的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 口腔医学是指口腔医学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 唾液腺功能障碍是癌症治疗的常见副作用,显著降低了患者的生活质量.
- 唾液功能对于日常活动,如吃饭,说话和吞至关重要.
- 抗癌疗法可以破坏唾液腺的复杂解剖学和生理学.
研究的目的:
- 审查癌症治疗对唾液腺功能的影响.
- 讨论在临床环境中量化异口 (口腔干燥) 的方法.
- 为癌症治疗诱导的唾液功能障碍提供当前和新兴的治疗方法.
主要方法:
- 与癌症治疗相关的唾液腺解剖学和生理学的综述.
- 分析施的临床量化方法,包括生活质量仪器和直接的唾液功能测量.
- 检查辐射诱导的唾液功能障碍的治疗策略,包括现有治疗方法和新方法的局限性.
主要成果:
- 化疗,骨髓移植,免疫疗法和放射疗法通过各种机制损害了唾液腺的功能.
- 经过验证的生命质量仪器和直接测量提供了对量化口症的不同观点.
- 目前的治疗方法,如sialogogues有局限性,突出需要创新的治疗方法.
结论:
- 了解唾液腺生理学是解决治疗引起的功能障碍的关键.
- 精确量化异口症对于患者管理至关重要.
- 新兴的细胞,基因和药理疗法对治疗癌症治疗引起的口腔干燥有前途.
更多相关视频
相关概念视频
Salivary Glands and Saliva
516
The salivary glands, of which there are three pairs known as the parotid, submandibular, and sublingual glands, play a crucial role in maintaining oral health and initiating the digestive process. Positioned near the ears, beneath the masseter muscle, the parotid glands secrete saliva into the oral cavity through the parotid duct of Stensen. Meanwhile, the submandibular glands, located on the floor of the mouth, secrete saliva through channels named submandibular ducts. The sublingual glands,...
516
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
204
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
204
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154


